Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma
Pancreatic cancer remains a highly malignant and challenging tumor with a dismal 5-year survival rate of only 13%. The majority of patients are diagnosed at advanced stages, where surgical options are limited, and prognosis is poor. Immunotherapy, particularly PD-1 inhibitors, has shown limited succ...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1458517/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846119356584427520 |
|---|---|
| author | Hongying Liu Yun Wang Qian Zhang Nengwen Ke |
| author_facet | Hongying Liu Yun Wang Qian Zhang Nengwen Ke |
| author_sort | Hongying Liu |
| collection | DOAJ |
| description | Pancreatic cancer remains a highly malignant and challenging tumor with a dismal 5-year survival rate of only 13%. The majority of patients are diagnosed at advanced stages, where surgical options are limited, and prognosis is poor. Immunotherapy, particularly PD-1 inhibitors, has shown limited success in pancreatic cancer due to its unique tumor immune microenvironment. However, certain genetic profiles, such as BRCA1/2 mutations, high tumor mutational burden (TMB), or microsatellite instability-high (MSI-H), may enhance sensitivity to these therapies. This report presents two cases of advanced pancreatic cancer with BRCA1/2 mutations treated with a combination of chemotherapy and immune checkpoint inhibitors. The first patient, with TMB-H and stable microsatellites, achieved complete remission after conversion therapy and remains disease-free for over two years post-surgery. The second patient, with MSI-H and low TMB, experienced significant tumor regression and improved quality of life with a prolonged progression-free survival, although the patient ultimately declined surgery. These cases suggest that combined chemotherapy and immunotherapy may offer a promising treatment option for select pancreatic cancer patients, particularly those with specific genetic profiles, warranting further investigation into personalized approaches to immunotherapy in this malignancy. |
| format | Article |
| id | doaj-art-c934b5c63fa34f84aa0ff3d63ceb1884 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-c934b5c63fa34f84aa0ff3d63ceb18842024-12-17T05:10:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14585171458517Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinomaHongying Liu0Yun Wang1Qian Zhang2Nengwen Ke3Department of Pancreatic Surgery, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, ChinaChengdu Shang Jin Nan Fu Hospital, Shang Jin Hospital of West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastrointestinal surgery, The Second People’s Hospital of Qujing City, Qujing, ChinaDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaPancreatic cancer remains a highly malignant and challenging tumor with a dismal 5-year survival rate of only 13%. The majority of patients are diagnosed at advanced stages, where surgical options are limited, and prognosis is poor. Immunotherapy, particularly PD-1 inhibitors, has shown limited success in pancreatic cancer due to its unique tumor immune microenvironment. However, certain genetic profiles, such as BRCA1/2 mutations, high tumor mutational burden (TMB), or microsatellite instability-high (MSI-H), may enhance sensitivity to these therapies. This report presents two cases of advanced pancreatic cancer with BRCA1/2 mutations treated with a combination of chemotherapy and immune checkpoint inhibitors. The first patient, with TMB-H and stable microsatellites, achieved complete remission after conversion therapy and remains disease-free for over two years post-surgery. The second patient, with MSI-H and low TMB, experienced significant tumor regression and improved quality of life with a prolonged progression-free survival, although the patient ultimately declined surgery. These cases suggest that combined chemotherapy and immunotherapy may offer a promising treatment option for select pancreatic cancer patients, particularly those with specific genetic profiles, warranting further investigation into personalized approaches to immunotherapy in this malignancy.https://www.frontiersin.org/articles/10.3389/fonc.2024.1458517/fullpancreatic adenocarcinomatumor reductioncase reportimmunotherapychemotherapy |
| spellingShingle | Hongying Liu Yun Wang Qian Zhang Nengwen Ke Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma Frontiers in Oncology pancreatic adenocarcinoma tumor reduction case report immunotherapy chemotherapy |
| title | Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma |
| title_full | Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma |
| title_fullStr | Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma |
| title_full_unstemmed | Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma |
| title_short | Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma |
| title_sort | case report achieving significant tumor reduction in advanced pancreatic adenocarcinoma |
| topic | pancreatic adenocarcinoma tumor reduction case report immunotherapy chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1458517/full |
| work_keys_str_mv | AT hongyingliu casereportachievingsignificanttumorreductioninadvancedpancreaticadenocarcinoma AT yunwang casereportachievingsignificanttumorreductioninadvancedpancreaticadenocarcinoma AT qianzhang casereportachievingsignificanttumorreductioninadvancedpancreaticadenocarcinoma AT nengwenke casereportachievingsignificanttumorreductioninadvancedpancreaticadenocarcinoma |